Quon P - Search Results

1

Rare coding variants in CHRNB2 reduce the likelihood of smoking.

Rajagopal VM, Watanabe K, Mbatchou J, Ayer A, Quon P, Sharma D, Kessler MD, Praveen K, Gelfman S, Parikshak N, Otto JM, Bao S, Chim SM, Pavlopoulos E, Avbersek A, Kapoor M, Chen E, Jones MB, Leblanc M, Emberson J, Collins R, Torres J, Morales PK, Tapia-Conyer R, Alegre J, Berumen J; GHS-REGN DiscovEHR collaboration; Regeneron Genetics Center; Shuldiner AR, Balasubramanian S, Abecasis GR, Kang HM, Marchini J, Stahl EA, Jorgenson E, Sanchez R, Liedtke W, Anderson M, Cantor M, Lederer D, Baras A, Coppola G. Rajagopal VM, et al. Among authors: quon p. Nat Genet. 2023 Jul;55(7):1138-1148. doi: 10.1038/s41588-023-01417-8. Epub 2023 Jun 12. Nat Genet. 2023. PMID: 37308787 Free PMC article.

2

Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.

Gu J, Kuznik A, Quon P, Chauhan A, Sravya TS, Raal FJ. Gu J, et al. Among authors: quon p. Eur J Prev Cardiol. 2023 Nov 30;30(17):1874-1880. doi: 10.1093/eurjpc/zwad203. Eur J Prev Cardiol. 2023. PMID: 37314419

3

Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing-Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non-Small-Cell Lung Cancer in the United States.

Zou D, Ye W, Hess LM, Bhandari NR, Ale-Ali A, Foster J, Quon P, Harris M. Zou D, et al. Among authors: quon p. J Mol Diagn. 2022 Aug;24(8):901-914. doi: 10.1016/j.jmoldx.2022.04.010. Epub 2022 Jun 7. J Mol Diagn. 2022. PMID: 35688357 Free article.

4

Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.

Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kisser A, Modesto I, Sharma PP. Sardesai A, et al. Among authors: quon p. J Med Econ. 2021 Jan-Dec;24(1):279-290. doi: 10.1080/13696998.2021.1881323. J Med Econ. 2021. PMID: 33502905 Free article.

5

An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.

Milev S, DiBonaventura MD, Quon P, Wern Goh J, Bourret J, Peeples-Lamirande K, Soonasra A, Cappelleri JC, Quirk D. Milev S, et al. Among authors: quon p. J Med Econ. 2019 Sep;22(9):859-868. doi: 10.1080/13696998.2019.1609481. Epub 2019 May 15. J Med Econ. 2019. PMID: 31012362 Free article.

6

Prevalence of distracted walking with mobile technology: an observational study of Calgary and Edmonton high school students.

Quon P, Lahey K, Grisdale M, Hagel B, Frost G, Belton K, Elliott A. Quon P, et al. Can J Public Health. 2019 Aug;110(4):506-511. doi: 10.17269/s41997-019-00200-9. Epub 2019 Mar 18. Can J Public Health. 2019. PMID: 30887456 Free PMC article.

7

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada.

Quon PL, Xiao Y, Sorensen S, Monfared AAT. Quon PL, et al. Pharmacoecon Open. 2019 Sep;3(3):321-331. doi: 10.1007/s41669-018-0112-1. Pharmacoecon Open. 2019. PMID: 30617952 Free PMC article.

8

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.

Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, Cohen AT. Lanitis T, et al. Among authors: quon p. BMC Health Serv Res. 2017 Jan 23;17(1):74. doi: 10.1186/s12913-017-1995-8. BMC Health Serv Res. 2017. PMID: 28114939 Free PMC article.

9

Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.

Lanitis T, Leipold R, Hamilton M, Rublee D, Quon P, Browne C, Cohen AT. Lanitis T, et al. Among authors: quon p. Clin Ther. 2016 Mar;38(3):478-93.e1-16. doi: 10.1016/j.clinthera.2016.01.020. Epub 2016 Feb 26. Clin Ther. 2016. PMID: 26922297

10

Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.

Quon P, Le HH, Raymond V, Mtibaa M, Moshyk A. Quon P, et al. J Med Econ. 2016 Jun;19(6):557-67. doi: 10.3111/13696998.2016.1141780. Epub 2016 Feb 3. J Med Econ. 2016. PMID: 26761644 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters